Examples of such multimodal biomarkers include positron emission tomography (PET) and magnetic resonance imaging to assess brain atrophy, electroencephalography (EEG) and functional near-infrared spectroscopy to study altered neural oscillations and brain functional connectivity and cerebrospinal fluid (CSF) analysis to measure amyloid-beta, tau and phosphorylated tau levels [3, 10–12]. The gene discussed is MAPT; the disease is Brain atrophy.